Rival GLP-1 pill matches Wegovy weight loss data, adding to competitive pressure on Novo Nordisk [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
Citi has kept its 'neutral' rating on Novo Nordisk (NYSE:NVO) after a rival company released clinical data showing its oral GLP-1 drug delivered weight loss broadly comparable to Novo's own obesity pill, adding to a growing list of competitive threats facing the Danish pharmaceutical giant. Structure Therapeutics published updated phase II results from its ACCESS obesity programme showing that aleniglipron, an oral small-molecule GLP-1 drug, achieved 16.3% placebo-adjusted weight loss at 44 weeks on the 180mg dose and up to 16.2% on the 120mg dose at 56 weeks. Novo's Wegovy Pill, by comparison, achieved 13.9% placebo-adjusted weight loss at 64 weeks. Citi flagged two features of the Structure data that could prove significant. First, there was no sign of a plateau across doses, suggesting patients may continue losing weight beyond the trial period if treatment is extended. Second, treatment discontinuations due to side effects were below 4% across the datasets, compared wit
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Novo Nordisk: The Illusion Of Cheap [Seeking Alpha]Seeking Alpha
- This Promising GLP-1 Drug Could Give Novo Nordisk Investors Renewed Hope for the Stock [Yahoo! Finance]Yahoo! Finance
- HSBC downgrades Eli Lilly, says shares are ‘priced to perfection' [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk A/S Investigated by the Portnoy Law FirmGlobeNewswire
- Novo Nordisk: Buy Hand Over Fist While Others Panic [Seeking Alpha]Seeking Alpha
NVO
Earnings
- 2/3/26 - Beat
NVO
Sec Filings
- 3/17/26 - Form 6-K
- 3/9/26 - Form 6-K
- 3/2/26 - Form 6-K
- NVO's page on the SEC website